AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16569546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12756094 — intervention group
Group type: COMPARATOR
Intervention: 0.05% clobetasol
Number of subjects: 20
Study 12756094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus
Number of subjects: 20
Study 10958144 — intervention group
Group type: EXPERIMENTAL
Intervention: CAI group (computer-assisted instruction)
Number of subjects: 100
Study 10958144 — intervention group
Group type: COMPARATOR
Intervention: No-CAI group (control)
Number of subjects: 100
Study 9071201 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (400 mg per day)
Number of subjects: 71
Study 9071201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg per day)
Number of subjects: 71
Study 9071201 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 71
Study 8369985 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at a speed that kept the exercise heart rate above the anaerobic threshold (group H: n = 12)
Number of subjects: 33
Study 8369985 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at a speed that kept the exercise heart rate below the anaerobic threshold (group M: n = 9)
Number of subjects: 33
Study 8369985 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C: n = 12)
Number of subjects: 33
Study 8369985 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups (group H and group M)
Number of subjects: 33
Study 3505530 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg of monosodium glutamate (MSG)
Number of subjects: 12
Study 3505530 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (equimolar to MSG)
Number of subjects: 12
Study 29421837 — intervention group
Group type: EXPERIMENTAL
Intervention: AHPLT group
Number of subjects: 124
Study 29421837 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus group
Number of subjects: 124
Study 27049290 — intervention group
Group type: EXPERIMENTAL
Intervention: Head cooling
Number of subjects: 196
Study 27049290 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 196
Study 25011439 — intervention group
Group type: EXPERIMENTAL
Intervention: OxMdG (oxaliplatin, 5-fluorouracil, and folic acid) with SIRT (Selective Internal Radiation Therapy)
Number of subjects: 0
Study 25011439 — intervention group
Group type: COMPARATOR
Intervention: OxMdG (oxaliplatin, 5-fluorouracil, and folic acid) alone
Number of subjects: 0
Study 25011439 — intervention group
Group type: EXPERIMENTAL
Intervention: OxMdG with SIRT
Number of subjects: 0
Study 25011439 — intervention group
Group type: COMPARATOR
Intervention: OxMdG alone
Number of subjects: 0
Study 21902854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT) - 8 sessions of 1 hour each
Number of subjects: 18
Study 21902854 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 18
Study 20816301 — intervention group
Group type: EXPERIMENTAL
Intervention: Distally displaced premolars (DDP) group (n=100)
Number of subjects: 2811
Study 20816301 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=500)
Number of subjects: 2811
Study 20816301 — intervention group
Group type: EXPERIMENTAL
Intervention: PDC-DDP group (experimental group 2)
Number of subjects: 2811
Study 20816301 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups 1 and 2
Number of subjects: 2811
Study 18795656 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 36
Study 17012105 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 24
Study 17012105 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 24
Study 12952774 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 12952774 — intervention group
Group type: COMPARATOR
Intervention: No music or other relaxation techniques
Number of subjects: 0
Study 11084174 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical analgesia with 75 mg of bupivacaine
Number of subjects: 61
Study 11084174 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 75 mg of bupivacaine to the fallopian tubes
Number of subjects: 61
Study 9080525 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR with rate drop sensing
Number of subjects: 284
Study 9080525 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 284
Study 8227469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times a day
Number of subjects: 97
Study 8227469 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 375 mg twice a day
Number of subjects: 97
Study 3485068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 221
Study 3485068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 29744762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern visually evoked potentials (VEP)
Number of subjects: 19
Study 29744762 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity assessments
Number of subjects: 19
Study 29744762 — intervention group
Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity
Number of subjects: 19
Study 29744762 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal nerve fiber layer (RNFL) thickness measurement
Number of subjects: 19
Study 29744762 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular thickness and volume measurements
Number of subjects: 19
Study 29744762 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field tests
Number of subjects: 19
Study 29787547 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted fascial closure (IFC)
Number of subjects: 136
Study 29787547 — intervention group
Group type: COMPARATOR
Intervention: Continuous fascial closure (CFC)
Number of subjects: 136
Study 26668251 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg balugrastim
Number of subjects: 256
Study 26668251 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg balugrastim
Number of subjects: 256
Study 26668251 — intervention group
Group type: COMPARATOR
Intervention: 6 mg pegfilgrastim
Number of subjects: 256
Study 26668251 — intervention group
Group type: EXPERIMENTAL
Intervention: balugrastim
Number of subjects: 256
Study 24568271 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parent Programme and Home Parent Support
Number of subjects: 126
Study 24568271 — intervention group
Group type: COMPARATOR
Intervention: Incredible Years Parent Programme alone
Number of subjects: 126
Study 22911148 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGBP+FR
Number of subjects: 24
Study 22911148 — intervention group
Group type: COMPARATOR
Intervention: LRYGBP
Number of subjects: 24
Study 19862815 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily
Number of subjects: 80
Study 19862815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice daily plus subcutaneous IFN 0.5 million U (MU) twice daily
Number of subjects: 80
Study 17359400 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal LMA (PLMA)
Number of subjects: 60
Study 17359400 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 60
Study 15182266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (antibiotics, ribavirin, corticosteroids, pulsed methylprednisolone if needed)
Number of subjects: 88
Study 15182266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 88
Study 11680329 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution (20 μg, increased to 40 μg after three doses, administered every 2 hours)
Number of subjects: 25
Study 11680329 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution
Number of subjects: 25
Study 9675624 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg chlorthalidone
Number of subjects: 100
Study 9675624 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg propranolol
Number of subjects: 100
Study 9675624 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg per day bopindolol
Number of subjects: 100
Study 7926702 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping through avoidance or seeking social support
Number of subjects: 92
Study 7926702 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital interaction (patient-rated)
Number of subjects: 92
Study 7926702 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital interaction (spouse-rated)
Number of subjects: 92
Study 7926702 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression levels
Number of subjects: 92
Study 2512630 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with amino acids (1000 ml of Vamin 14g N/l)
Number of subjects: 10
Study 2512630 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition without amino acids
Number of subjects: 10
Study 28619129 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamlodipine besylate 2.5-mg tablet (test)
Number of subjects: 50
Study 28619129 — intervention group
Group type: COMPARATOR
Intervention: Levamlodipine besylate 2.5-mg marketed counterpart (reference)
Number of subjects: 50
Study 31916092 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical oncologists
Number of subjects: 289
Study 31916092 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical oncologists
Number of subjects: 289
Study 31464581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50, 100, or 200 mg
Number of subjects: 4439
Study 31464581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4439
Study 31464581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 4439
Study 28459835 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity exercise (SS-EX)
Number of subjects: 23
Study 28459835 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (MOD-EX)
Number of subjects: 23
Study 28459835 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment-themed video game (ET-VG)
Number of subjects: 23
Study 28459835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness-themed video game (FT-VG)
Number of subjects: 23
Study 25209926 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daily of self-administered vaginal progesterone
Number of subjects: 385
Study 25209926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 22936007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tideglusib (400, 600, 800, 1,000 mg)
Number of subjects: 30
Study 22936007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21349646 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide containing bio-cellulose dressing (group B)
Number of subjects: 60
Study 21349646 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream (group A)
Number of subjects: 60
Study 19906334 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical termination of pregnancy (MTOP) - mifepristone 200 mg orally followed by misoprostol 36-48 hours later
Number of subjects: 1877
Study 19906334 — intervention group
Group type: COMPARATOR
Intervention: Surgical termination of pregnancy (STOP) - misoprostol 400 micrograms 2 hours before procedure, performed under general anaesthesia using vacuum aspiration
Number of subjects: 1877
Study 16952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal spermatogenesis (n = 8)
Number of subjects: 17
Study 16952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Maturation arrest (n = 5)
Number of subjects: 17
Study 16952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertoli cell‐only syndrome (n = 4)
Number of subjects: 17
Study 14762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled infliximab 10 mg/kg
Number of subjects: 573
Study 14762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled infliximab 5 mg/kg
Number of subjects: 573
Study 14762776 — intervention group
Group type: COMPARATOR
Intervention: Episodic infliximab (placebo)
Number of subjects: 573
Study 11780880 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal rTMS
Number of subjects: 12
Study 11780880 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal rTMS
Number of subjects: 12
Study 9137509 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV chemotherapy (mitomycin C, methotrexate, vincristine) alone
Number of subjects: 102
Study 9137509 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with medroxyprogesterone acetate
Number of subjects: 102
Study 9137509 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with prednisolone
Number of subjects: 102
Study 9137509 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 102
Study 9137509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox's proportional hazard model
Number of subjects: 102
Study 9137509 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark method (3-month)
Number of subjects: 102
Study 8106223 — intervention group
Group type: EXPERIMENTAL
Intervention: 6mg buccal prochlorperazine one hour before surgery
Number of subjects: 52
Study 3661963 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 120
Study 3661963 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 120
Study 3661963 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 120
Study 3661963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31376290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling (US)
Number of subjects: 17
Study 31376290 — intervention group
Group type: COMPARATOR
Intervention: Air polishing (AP)
Number of subjects: 17
Study 28715811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (3-month scheduled followed by 9-month pro re nata)
Number of subjects: 18
Study 28715811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 18
Study 25430728 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intermediate care
Number of subjects: 18
Study 25430728 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical ward care
Number of subjects: 18
Study 23621388 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix rhythm therapy
Number of subjects: 15
Study 23621388 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 15
Study 21566425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HF HD)
Number of subjects: 42
Study 21566425 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (Control)
Number of subjects: 42
Study 19076173 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (TP) using low molecular weight heparins
Number of subjects: 0
Study 19076173 — intervention group
Group type: EXPERIMENTAL
Intervention: New classes of oral anticoagulants (e.g., dabigatran, rivaroxiban)
Number of subjects: 0
Study 19076173 — intervention group
Group type: COMPARATOR
Intervention: NICE guidelines for VTE prevention
Number of subjects: 0
Study 16960941 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg qd
Number of subjects: 611
Study 16960941 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg qd
Number of subjects: 611
Study 16960941 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg bid
Number of subjects: 611
Study 16960941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 12631041 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. propacetamol 40 mg kg(‐1)
Number of subjects: 64
Study 12631041 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. propacetamol 20 mg kg(‐1)
Number of subjects: 64
Study 12631041 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. propacetamol 10 mg kg(‐1)
Number of subjects: 64
Study 12631041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12631041 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (H, I, L)
Number of subjects: 64
Study 12631041 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. propacetamol
Number of subjects: 64
Study 11789281 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica sinensis injection
Number of subjects: 60
Study 11789281 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose injection
Number of subjects: 60
Study 9089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest
Number of subjects: 275
Study 9089558 — intervention group
Group type: COMPARATOR
Intervention: Estraderm TTS
Number of subjects: 275
Study 7682581 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen challenge
Number of subjects: 10
Study 7682581 — intervention group
Group type: COMPARATOR
Intervention: Codeine challenge
Number of subjects: 10
Study 7682581 — intervention group
Group type: COMPARATOR
Intervention: Buffer diluent
Number of subjects: 10
Study 7682581 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen challenge after codeine
Number of subjects: 10
Study 7682581 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with immunoglobulin G levels
Number of subjects: 10
Study 7682581 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with histamine levels
Number of subjects: 10
Study 3535010 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at night
Number of subjects: 59
Study 3535010 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine twice daily
Number of subjects: 59
Study 30295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Sedation (PCS)
Number of subjects: 40
Study 30295410 — intervention group
Group type: COMPARATOR
Intervention: Radiologist Controlled Sedation (RCS)
Number of subjects: 40
Study 26661319 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL up-titrated to 200 mg/day
Number of subjects: 75
Study 26661319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 24573506 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate IUD insertion after abortion under general or paracervical anesthesia
Number of subjects: 142
Study 24573506 — intervention group
Group type: COMPARATOR
Intervention: Delayed IUD insertion during the next menstrual cycle without anesthesia
Number of subjects: 142
Study 22429325 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy promotion training programme (six sessions)
Number of subjects: 63
Study 22429325 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 63
Study 19608185 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strain L. plantarum (DSM 9843)
Number of subjects: 16
Study 19608185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18804887 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based educational system (LAY)
Number of subjects: 89
Study 15690537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac / steroids
Number of subjects: 698
Study 15690537 — intervention group
Group type: COMPARATOR
Intervention: Tac / Dac
Number of subjects: 698
Study 12395004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 73
Study 12395004 — intervention group
Group type: COMPARATOR
Intervention: No Ultrasound (Control)
Number of subjects: 73
Study 11871829 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (80 mg intramuscularly once weekly for 6 weeks)
Number of subjects: 40
Study 11871829 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (40 mg/day in a 'tailing‐off' regimen)
Number of subjects: 40
Study 9647268 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg via metered-dose inhaler twice daily
Number of subjects: 539
Study 9647268 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 microg four times daily
Number of subjects: 539
Study 7718048 — intervention group
Group type: EXPERIMENTAL
Intervention: Medline search for randomised clinical trials
Number of subjects: 0
Study 7718048 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted means for sensitivity across all studies
Number of subjects: 0
Study 7718048 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted mean for precision
Number of subjects: 0
Study 2493023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg, orally)
Number of subjects: 14
Study 2493023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31192625 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments using logarithmic‐transformed ANOVA (LANOVA) and logarithmic‐transformed ANCOVA (LANCOVA)
Number of subjects: 0
Study 31192625 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed methods (LANOVA and LANCOVA)
Number of subjects: 0
Study 31192625 — intervention group
Group type: EXPERIMENTAL
Intervention: Logarithmic transformations
Number of subjects: 0
Study 30654026 — intervention group
Group type: EXPERIMENTAL
Intervention: App+Coach
Number of subjects: 180
Study 30654026 — intervention group
Group type: COMPARATOR
Intervention: App
Number of subjects: 180
Study 30654026 — intervention group
Group type: COMPARATOR
Intervention: Clinic
Number of subjects: 180
Study 28427388 — intervention group
Group type: COMPARATOR
Intervention: Standard Speech Therapy (SST) for 45 minutes, twice a week for 9 months
Number of subjects: 0
Study 28427388 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement, Cognition and Narration of emotions treatment (MCNT) for 3 hours per day, 5 days a week for 9 months
Number of subjects: 0
Study 28427388 — intervention group
Group type: COMPARATOR
Intervention: Waiting list for Standard Speech Therapy (SST) for 9 months
Number of subjects: 0
Study 25256361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical exposure group treatment using Gestalt empty‐chair method
Number of subjects: 119
Study 25256361 — intervention group
Group type: COMPARATOR
Intervention: Supportive group treatment
Number of subjects: 119
Study 25256361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical exposure group treatment
Number of subjects: 119
Study 23895180 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) ON
Number of subjects: 32